$JD HEALTH(06618)$ delivered strong Q3 2025 results, with revenue up 29% and profit nearly doubling. Its share price has rebounded sharply, rising 144% this year after falling over 90% from 2020–2023. The company expanded partnerships with major pharma and medical device firms and strengthened its AI-driven Internet healthcare ecosystem. User activity and service scale continue to grow, with over 200 million active users and 500,000 daily consultation orders. Analysts believe the pharmaceutical segment will remain the key growth driver as JD Health deepens its full-cycle health management services.

$Stryker(SYK)$ Outlook FY Organic Net Sales Growth 9.8-10.2%

Major global banks — including Goldman Sachs, Morgan Stanley, and JPMorgan — have all turned bullish on Chinese assets, projecting a multi-year “slow bull market” with roughly 30% upside potential in key indices by 2027. Foreign inflows exceeding $200 billion are expected as valuations remain deeply discounted, AI investment accelerates, and China’s new Five-Year Plan supports structural growth. Institutions are particularly overweight in technology, high-dividend, and internet sectors, with Alibaba (BABA) emerging as a top conviction pick. $Alibaba(BABA)$ offers asymmetric upside: its valuation sits near historic lows, earnings momentum is recovering, and policy tailwinds favor digital and AI-driven platforms.

$Hca Healthcare Inc(HCA)$ is putting up strong numbers in 2025 — up 41.98% year-to-date, outperforming the broader healthcare sector. The company posted EPS of $5.65, indicating solid earnings momentum. The stock broke into all-time high territory today, printing $443.41. Momentum remains strong, with institutional flow favoring the breakout. Keep an eye on volume follow-through and macro headwinds, but technically, this is a clear leader.